Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder

The treatment portion of this study consists of a 40 minute TMS session 5 days a week (Mon-Fri) for 6 weeks.  Other visits include an intake assessment, a pre-treatment MRI, a post-treatment assessment and MRI, and a 6 month follow up visit.  Participants are paid for both MRI visits, the post-treatment visit and the follow up visit.  Half of participants will receive real TMS, while the other half will receive sham (placebo) TMS.

Organization: 
Hartford Hospital’s Institute of Living, Yale University School of Medicine
Principal Investigator: 
Gretchen Diefenbach, PhD
Eligibility Criteria: 

Individuals with the following will be considered for this study:

 

  • Diagnosed with GAD as the principal or co-principal disorder
  • Clinical Global Impression Score ≥ 4
  • Hamilton Anxiety Rating Scale ≥ 18
  • Hamilton Rating Scale for Depression ≤ 17
  • Fluency in English
  • Capacity to understand the nature of the study and willingness to sign informed consent form
Exclusion Criteria: 

Individuals with the following will not be considered for the study:

 

  • History of epilepsy or head trauma (LOC > 5 minutes) within the past 6 months. Lifetime history of increased intracranial pressure, seizure disorder, stroke, brain tumor, multiple sclerosis, or brain surgery
  • A review of patient medications by the study physician indicates an increased risk of seizure
  • An active autoimmune, endocrine, viral, or vascular disorder affecting the brain; any unstable cardiac disease; hypertension; or severe renal or liver insufficiency
  • Substance use disorder or post traumatic stress disorder within the past 6 months. Lifetime obsessive-compulsive disorder,bipolar disorder, psychotic disorder, mental retardation, or pervasive developmental disorder. Any psychotic features, including dementia or delirium
  • Concurrent psychotherapy and unwillingness to discontinue
  • Medication change within past 3 months
  • Current serious suicidal or homicidal ideation, and/or serious suicidal attempt within past 6 months
  • Serious, unstable, or terminal medical condition or clinically judged too psychiatrically unstable to participate in the study
  • Any contraindication for participation in MRI scan
Contact: 
Laura Bragdon, 860-545-7386, lbragdon@harthosp.org
Location: 
Hartford, CT
State: 
Connecticut
Study End Date: 
Sun, 2014-06-01

Contact ADAA

8701 Georgia Ave. #412
Silver Spring, MD 20910

240.485.1001

Contact ADAA

Request Publications

FacebookTwitterRSS

 

ADAA is a national nonprofit organization dedicated to the prevention, treatment, and cure of anxiety, OCD, PTSD, depression, and related disorders and to improving the lives of all people who suffer from them.